Analyzing the Global Pharmaceutical Industry 2015

Analyzing the Global Pharmaceutical Industry 2015

The global presence of the pharmaceutical industry is evident with the roll out of continent specific R&D programs and drugs which help companies maximize penetration of markets and garner increased revenues with intercontinental treatment demand of patients being serviced from often one or two mega research centers in the continent.

By contribution of size, the pharmaceutical industry is majorly dominant at the US, Asia Pacific. Led by these markets, the total world consumption in sales of pharmaceutical products has displayed strong growth and is expected to grow further with expanding populations in emerging markets.

However, in recent times, austerity measures across the world along with many countires imposing cutbacks on healthcare spending (particularly in Europe), has hit the pharmaceutical industry. Furthermore, the loss of patent for many blockbuster drugs during the years 2010-2015 is also going to have a big impact on the global pharmaceutical industry. However, generic manufacturers are likely to benefit from this as they are poised to capture a substantial portion of revenues with their generic versions of these drugs.

Aruvian’s Research’s report – Analyzing the Global Pharmaceutical Industry - presents a complete analysis of the global pharmaceutical industry by setting up an industry demarcation and providing a study on marketing dynamic of the industry like segments active in the industry, competitive activity and the overall market outlook. The global pharmaceutical industry is analyzed in this in-depth report through industry statistics (data ranging from 2009 to 2018), industry value, industry segmentation, an analysis of market share, competitive landscape and an industry forecast till 2018.

The role played by the OTC pharmaceuticals in the global pharma industry is also explained in detail in the report with the intense marketing efforts prevalent in the industry in order to push the inclusion of OTC pharmaceuticals into the buy – store segment of home segments. The often competed and hotly contested area of Generics with the rapid proliferative competition from the low cost suppliers in the emerging markets is also explained in this report with the forecast for the industry which looks upbeat.

We analyze the global pharmaceutical industry, the global OTC market and the global generics industry through a Porter’s Five Forces Framework analysis.

We look at the patent expiries that the global pahrmaceutical industry is going through along with what the impact of this is going to be on the entire industry.

Industry structure is analyzed through a look at research and development pipelines, defense against generic competition, restructuring and outsourcing as well as the formation of strategic alliances. Analyzing the global pharmaceutical industry further, we take a look at the barriers to entry facing the industry, lifecycle of a drug, industry cost structure, industry trends and innovation, business environment and globalization of the global pharmaceutical industry.

Factors driving growth and change in the global pharmaceutical industry are analyzed. Analyzed factors include the emergence of new product lines, reasons for industry growth, opportunities in various CNS disorders and oncology research, ongoing commercialization of dormant compounds along with a look at the role of biosimilars in the industry. Moving on, we also analyzed the various challenges facing the global pharmaceutical industry and how the industry is dealing with them.

The TRIPS agreement has been a point of debate in the globally wherein the issues are equally contested for the developing as well as the developed countries and the options of flexibility which have inculcated in the report are explained in this report. Apart from this, another interesting phenomenon explained in this report is the practice of “offshoring” amongst the pharma companies and the value chains which have been developed to service them globally.

An analysis of the key pharmaceutical markets is included in the report. We analyze each market through industry statistics, industry value analysis, geographic segmentation, industry trends and production trends (wherever available), market share analysis, competitive landscape and an industry outlook to 2018. A total of 27 markets analyzed in our report include:

• Australia
• Belgium
• Brazil
• Canada
• China
• Czech Republic
• Denmark
• France
• Germany
• Hungary
• India
• Italy
• Japan
• Mexico
• Netherlands
• New Zealand
• Norway
• Poland
• Russia
• Singapore
• South Africa
• South Korea
• Spain
• Sweden
• Taiwan
• United Kingdom
• United States

Moving on, a comprehensive analysis of the major industry players is undertaken. The players are analyzed through a corporate profile, an analysis of their major business segments, a financial analysis, ratio analysis, a look at their major products & services as well as a SWOT analysis. A total of 46 companies in our report.

With over 200 figures & tables, this highly insightful and analytical report from Aruvian Research is a complete & up-to-date coverage of the Global Pharmaceutical Industry.


Executive Summary
Section 1: Analyzing the Global Pharmaceutical Industry
A. Historical Perspective of the Global Pharmaceutical Industry
B. Analysis of the Global Pharmaceutical Industry
B.1 Industry Definitions
B.1.1 Pharmaceutical Industry
B.1.2 Bulk Drugs
B.1.3 Formulations
B.2 Industry Statistics
B.3 Industry Value Analysis
B.4 Market Segments
B.5 Market Share Analysis
B.6 Competition in the Industry
B.7 Market Forecast
C. Global Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
C.1 Introduction
C.2 Bargaining Power of Buyers
C.3 Bargaining Power of Suppliers
C.4 Competitive Rivalry in the Industry
C.5 Threat of New Entrants
C.6 Threat of Substitutes
D. Analysis of the Global OTC Pharmaceutical Industry
D.1 Industry Definition
D.2 Industry Statistics
D.3 Industry Value Analysis
D.4 Market Segments
D.5 Distribution Channels
D.6 Market Share Analysis
D.7 Market Forecast
E. Global OTC Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
E.1 Introduction
E.2 Bargaining Power of Buyers
E.3 Bargaining Power of Suppliers
E.4 Competitive Rivalry in the Industry
E.5 Threat of New Entrants
E.6 Threat of Substitutes
F. Analysis the Global Generics Industry
F.1 Industry Definition
F.2 Industry Statistics
F.3 Industry Value & Volume Analysis
F.4 Market Segments
F.5 Industry Structure
F.6 Patent Expiries
F.7 Patent Expiries by Therapeutic Areas
F.8 Research & Development in the Industry
F.8.1 Super Generics
F.8.2 Biosimilars
F.9 Market Forecast
G. Global Generics Industry: Porter’s Five Forces Strategy Analysis
G.1 Introduction
G.2 Bargaining Power of Buyers
G.3 Bargaining Power of Suppliers
G.4 Competitive Rivalry in the Industry
G.5 Threat of New Entrants
G.6 Threat of Substitutes
H. Structure of the Global Pharmaceutical Industry
H.1 R&D Pipelines
H.2 Defense against Generic Competition
H.3 Looking at Restructuring and Outsourcing
H.4 Strategic Alliances
I. Analyzing the Industry
I.1 Barriers to Entry
I.2 Lifecycle of a Drug
I.2.1 The Patent System
I.2.2 Drug Lifecycle
I.3 Industry Cost Structure
I.3.1 Types of Costs
I.3.2 Evidence on Cost Structure
I.3.3 Increasing Costs & Risks of Developing New Drugs
I.3.4 Conclusion
I.4 Trends in the Global Pharmaceutical Industry
I.5 Business Environment
I.6 Industry Innovation
I.7 Globalization of the Pharmaceutical Industry
I.8 Role of Genomics
J. Factors Driving Growth & Change in the Global Pharmaceutical Industry
J.1 Introduction
J.2 Growth in the Pharma Market
J.3 Reasons for Growth
J.4 New Product Lines
J.5 Opportunities in CNS Disorders & Oncology Research
J.6 Commercialization of Dormant Compounds
J.7 Generic/Biosimilar Versions of Biologics
K. Challenges Facing the Global Pharmaceutical Industry
K.1 Parallel Trade
K.2 Rising Cost of Healthcare
K.3 Immense Pressure on Industry Revenues
K.4 Uncertainty in Pipeline
K.5 Increasing Risks
K.6 Issues with Outcome-based Pricing
N. Offshoring in the Pharmaceutical Sector
N.1 Introduction
N.1.1 What is Offshoring?
N.1.2 Analyzing the Pharma Value Chain
N.1.3 Employment Scenario of the Pharmaceutical Industry
N.1.4 Why Offshore?
N.1.5 Primary Offshoring Locations
N.2 Offshoring of R&D
N.2.1 India
N.2.2 China
N.2.3 Growth Factors
N.2.4 Challenges & Barriers to Offshoring R&D
N.3 Offshoring of Pharmaceutical Manufacturing Processes
N.3.1 Overview
N.3.2 Biologics Manufacturing
N.3.3 API Manufacturing
N.3.4 Final Dosage Manufacturing
N.3.5 Growth Factors
N.3.6 Challenges & Barriers to Offshoring Manufacturing Processes
Section 2: Analyzing the Global Pharmaceutical Markets
A. Pharmaceutical Industry in Australia
A.1 Industry Statistics
A.2 Industry Value Analysis
A.3 Geographic Segmentation
A.4 Industry Trends
A.5 Production Trends
A.6 Market Share Analysis
A.7 Competition in the Industry
A.8 Industry Outlook
B. Pharmaceutical Industry in Belgium
B.1 Industry Statistics
B.2 Industry Value Analysis
B.3 Geographic Segmentation
B.4 Market Share Analysis
B.5 Competition in the Industry
B.6 Industry Outlook
C. Pharmaceutical Industry in Brazil
C.1 Industry Statistics
C.2 Industry Value Analysis
C.3 Geographic Segmentation
C.4 Market Share Analysis
C.5 Competition in the Industry
C.6 Industry Outlook
D. Pharmaceutical Industry in Canada
D.1 Industry Statistics
D.2 Industry Value Analysis
D.3 Geographic Segmentation
D.4 Market Share Analysis
D.5 Competition in the Industry
D.6 Industry Outlook
E. Pharmaceutical Industry in China
E.1 Industry Statistics
E.2 Industry Value Analysis
E.3 Geographic Segmentation
E.4 Industry Trends
E.5 Production Trends
E.6 Regulatory Framework
E.7 Market for Traditional Chinese Medicine
E.8 Market Share Analysis
E.9 Competition in the Industry
E.10 Industry Outlook
F. Pharmaceutical Industry in Czech Republic
F.1 Industry Statistics
F.2 Industry Value Analysis
F.3 Geographic Segmentation
F.4 Market Share Analysis
F.5 Competition in the Industry
F.6 Industry Outlook
G. Pharmaceutical Industry in Denmark
G.1 Industry Statistics
G.2 Industry Value Analysis
G.3 Geographic Segmentation
G.4 Market Share Analysis
G.5 Competition in the Industry
G.6 Industry Outlook
H. Pharmaceutical Industry in France
H.1 Industry Statistics
H.2 Industry Value Analysis
H.3 Geographic Segmentation
H.4 Market Share Analysis
H.5 Competition in the Industry
H.6 Industry Outlook
I. Pharmaceutical Industry in Germany
I.1 Industry Statistics
I.2 Industry Value Analysis
I.3 Geographic Segmentation
I.4 Market Share Analysis
I.5 Competition in the Industry
I.6 Industry Outlook
J. Pharmaceutical Industry in Hungary
J.1 Industry Statistics
J.2 Industry Value Analysis
J.3 Geographic Segmentation
J.4 Market Share Analysis
J.5 Competition in the Industry
J.6 Industry Outlook
K. Pharmaceutical Industry in India
K.1 Industry Statistics
K.2 Industry Value Analysis
K.3 Geographic Segmentation
K.4 Industry Trends
K.5 Production Trends
K.6 Market Share Analysis
K.7 Competition in the Industry
K.8 Industry Outlook
L. Pharmaceutical Industry in Italy
L.1 Industry Statistics
L.2 Industry Value Analysis
L.3 Geographic Segmentation
L.4 Market Share Analysis
L.5 Competition in the Industry
L.6 Industry Outlook
M. Pharmaceutical Industry in Japan
M.1 Industry Statistics
M.2 Industry Value Analysis
M.3 Geographic Segmentation
M.4 Industry Trends
M.5 Production Trends
M.6 Market Share Analysis
M.7 Competition in the Industry
M.8 Industry Outlook
N. Pharmaceutical Industry in Mexico
N.1 Industry Statistics
N.2 Industry Value Analysis
N.3 Geographic Segmentation
N.4 Market Share Analysis
N.5 Competition in the Industry
N.6 Industry Outlook
O. Pharmaceutical Industry in Netherlands
O.1 Industry Statistics
O.2 Industry Value Analysis
O.3 Geographic Segmentation
O.4 Market Share Analysis
O.5 Competition in the Industry
O.6 Industry Outlook
P. Pharmaceutical Industry in New Zealand
P.1 Industry Statistics
P.2 Industry Value Analysis
P.3 Geographic Segmentation
P.4 Market Share Analysis
P.5 Competition in the Industry
P.6 Industry Outlook
Q. Pharmaceutical Industry in Norway
Q.1 Industry Statistics
Q.2 Industry Value Analysis
Q.3 Geographic Segmentation
Q.4 Market Share Analysis
Q.5 Competition in the Industry
Q.6 Industry Outlook
R. Pharmaceutical Industry in Poland
R.1 Industry Statistics
R.2 Industry Value Analysis
R.3 Geographic Segmentation
R.4 Market Share Analysis
R.5 Competition in the Industry
R.6 Industry Outlook
S. Pharmaceutical Industry in Russia
S.1 Industry Statistics
S.2 Industry Value Analysis
S.3 Geographic Segmentation
S.4 Market Share Analysis
S.5 Competition in the Industry
S.6 Industry Outlook
T. Pharmaceutical Industry in Singapore
T.1 Industry Statistics
T.2 Industry Value Analysis
T.3 Geographic Segmentation
T.4 Market Share Analysis
T.5 Competition in the Industry
T.6 Industry Outlook
U. Pharmaceutical Industry in South Africa
U.1 Industry Statistics
U.2 Industry Value Analysis
U.3 Geographic Segmentation
U.4 Market Share Analysis
U.5 Competition in the Industry
U.6 Industry Outlook
V. Pharmaceutical Industry in South Korea
V.1 Industry Statistics
V.2 Industry Value Analysis
V.3 Geographic Segmentation
V.4 Market Share Analysis
V.5 Competition in the Industry
V.6 Industry Outlook
W. Pharmaceutical Industry in Spain
W.1 Industry Statistics
W.2 Industry Value Analysis
W.3 Geographic Segmentation
W.4 Market Share Analysis
W.5 Competition in the Industry
W.6 Industry Outlook
X. Pharmaceutical Industry in Sweden
X.1 Industry Statistics
X.2 Industry Value Analysis
X.3 Geographic Segmentation
X.4 Market Share Analysis
X.5 Competition in the Industry
X.6 Industry Outlook
Y. Pharmaceutical Industry in Taiwan
Y.1 Industry Statistics
Y.2 Industry Value Analysis
Y.3 Geographic Segmentation
Y.4 Market Share Analysis
Y.5 Competition in the Industry
Y.6 Industry Outlook
Z. Pharmaceutical Industry in United Kingdom
Z.1 Industry Statistics
Z.2 Industry Value Analysis
Z.3 Geographic Segmentation
Z.4 Market Share Analysis
Z.5 Competition in the Industry
Z.6 Industry Outlook
AA. Pharmaceutical Industry in the United States
AA.1 Industry Statistics
AA.2 Industry Value Analysis
AA.3 Geographic Segmentation
AA.4 Market Share Analysis
AA.5 Competition in the Industry
AA.6 Industry Outlook
Section 3: Analyzing the Major Market Players
A. Abbott Laboratories
A.1 Corporate Profile
A.2 Business Segment Analysis
A.3 Financial Analysis
A.4 Ratio Analysis
A.5 Major Products & Services
A.6 SWOT Analysis
B. Allergan, Inc.
B.1 Corporate Profile
B.2 Business Segment Analysis
B.3 Financial Analysis
B.4 Ratio Analysis
B.5 Major Products & Services
B.6 SWOT Analysis
C. Amgen, Inc.
C.1 Corporate Profile
C.2 Business Segment Analysis
C.3 Financial Analysis
C.4 Ratio Analysis
C.5 Major Products & Services
C.6 SWOT Analysis
D. Apotex, Inc.
D.1 Corporate Profile
D.2 Business Segment Analysis
D.3 Financial Analysis
D.4 Ratio Analysis
D.5 Major Products & Services
D.6 SWOT Analysis
E. Aspen Pharmacare Holdings Limited
E.1 Corporate Profile
E.2 Business Segment Analysis
E.3 Financial Analysis
E.4 Ratio Analysis
E.5 Major Products & Services
E.6 SWOT Analysis
F. Astellas Pharma
F.1 Corporate Profile
F.2 Business Segment Analysis
F.3 Financial Analysis
F.4 Ratio Analysis
F.5 Major Products & Services
F.6 SWOT Analysis
G. AstraZeneca
G.1 Corporate Profile
G.2 Business Segment Analysis
G.3 Financial Analysis
G.4 Ratio Analysis
G.5 Major Products & Services
G.6 SWOT Analysis
H. Baxter International
H.1 Corporate Profile
H.2 Business Segment Analysis
H.3 Financial Analysis
H.4 Ratio Analysis
H.5 Major Products & Services
H.6 SWOT Analysis
I. Bayer AG
I.1 Corporate Profile
I.2 Business Segment Analysis
I.3 Financial Analysis
I.4 Ratio Analysis
I.5 Major Products & Services
I.6 SWOT Analysis
J. Boehringer Ingelheim
J.1 Corporate Profile
J.2 Business Segment Analysis
J.3 Financial Analysis
J.4 Ratio Analysis
J.5 Major Products & Services
J.6 SWOT Analysis
K. Bristol-Myers Squibb
K.1 Corporate Profile
K.2 Business Segment Analysis
K.3 Financial Analysis
K.4 Ratio Analysis
K.5 Major Products & Services
K.6 SWOT Analysis
L. Chugai Pharmaceutical
L.1 Corporate Profile
L.2 Business Segment Analysis
L.3 Financial Analysis
L.4 Ratio Analysis
L.5 Major Products & Services
L.6 SWOT Analysis
M. Daewoong Pharmaceutical Co Ltd.
M.1 Corporate Profile
M.2 Business Segment Analysis
M.3 Financial Analysis
M.4 Ratio Analysis
M.5 Major Products & Services
M.6 SWOT Analysis
N. Daiichi Sankyo Company
N.1 Corporate Profile
N.2 Business Segment Analysis
N.3 Financial Analysis
N.4 Ratio Analysis
N.5 Major Products & Services
N.6 SWOT Analysis
O. Eisai Co., Ltd
O.1 Corporate Profile
O.2 Business Segment Analysis
O.3 Financial Analysis
O.4 Ratio Analysis
O.5 Major Products & Services
O.6 SWOT Analysis
P. Eli Lilly and Company
P.1 Corporate Profile
P.2 Business Segment Analysis
P.3 Financial Analysis
P.4 Ratio Analysis
P.5 Major Products & Services
P.6 SWOT Analysis
Q. F. Hoffmann-La Roche
Q.1 Corporate Profile
Q.2 Business Segment Analysis
Q.3 Financial Analysis
Q.4 Ratio Analysis
Q.5 Major Products & Services
Q.6 SWOT Analysis
R. GlaxoSmithKline Plc
R.1 Corporate Profile
R.2 Business Segment Analysis
R.3 Financial Analysis
R.4 Ratio Analysis
R.5 Major Products & Services
R.6 SWOT Analysis
S. Johnson & Johnson
S.1 Corporate Profile
S.2 Business Segment Analysis
S.3 Financial Analysis
S.4 Ratio Analysis
S.5 Major Products & Services
S.6 SWOT Analysis
T. Lupin Limited
T.1 Corporate Profile
T.2 Business Segment Analysis
T.3 Financial Analysis
T.4 Ratio Analysis
T.5 Major Products & Services
T.6 SWOT Analysis
U. Merck & Co.
U.1 Corporate Profile
U.2 Business Segment Analysis
U.3 Financial Analysis
U.4 Ratio Analysis
U.5 Major Products & Services
U.6 SWOT Analysis
V. Novartis AG
V.1 Corporate Profile
V.2 Business Segment Analysis
V.3 Financial Analysis
V.4 Ratio Analysis
V.5 Major Products & Services
V.6 SWOT Analysis
W. Pfizer
W.1 Corporate Profile
W.2 Business Segment Analysis
W.3 Financial Analysis
W.4 Ratio Analysis
W.5 Major Products & Services
W.6 SWOT Analysis
X. Richter Gedeon Vegyeszeti Gyar Nyrt
X.1 Corporate Profile
X.2 Business Segment Analysis
X.3 Financial Analysis
X.4 Ratio Analysis
X.5 Major Products & Services
X.6 SWOT Analysis
Y. Sanofi SA
Y.1 Corporate Profile
Y.2 Business Segment Analysis
Y.3 Financial Analysis
Y.4 Ratio Analysis
Y.5 Major Products & Services
Y.6 SWOT Analysis
Z. Shanghai Pharmaceuticals Holding Co. Ltd.
Z.1 Corporate Profile
Z.2 Business Segment Analysis
Z.3 Financial Analysis
Z.4 Ratio Analysis
Z.5 Major Products & Services
Z.6 SWOT Analysis
AA. Sumitomo Dainippon Pharma
AA.1 Corporate Profile
AA.2 Business Segment Analysis
AA.3 Financial Analysis
AA.4 Ratio Analysis
AA.5 Major Products & Services
AA.6 SWOT Analysis
BB. Takeda Pharmaceutical Company Limited
BB.1 Corporate Profile
BB.2 Business Segment Analysis
BB.3 Financial Analysis
BB.4 Ratio Analysis
BB.5 Major Products & Services
BB.6 SWOT Analysis
CC. Teva Pharmaceutical Industries
CC.1 Corporate Profile
CC.2 Business Segment Analysis
CC.3 Financial Analysis
CC.4 Ratio Analysis
CC.5 Major Products & Services
CC.6 SWOT Analysis
DD. Aurobindo Pharma Ltd
DD.1 Corporate Profile
DD.2 Business Segment Analysis
DD.3 Financial Analysis
DD.4 Ratio Analysis
DD.5 Major Products & Services
EE. Cadila Healthcare
EE.1 Corporate Profile
EE.2 Business Segment Analysis
EE.3 Financial Analysis
EE.4 Ratio Analysis
EE.5 Major Products & Services
FF. China National Accord Medicines Corporation Ltd
FF.1 Corporate Profile
FF.2 Business Segment Analysis
FF.3 Financial Analysis
FF.4 Ratio Analysis
FF.5 Major Products & Services
GG. Cipla Ltd
GG.1 Corporate Profile
GG.2 Business Segment Analysis
GG.3 Financial Analysis
GG.4 Ratio Analysis
GG.5 Major Products & Services
HH. Dr. Reddy's Laboratories Limited
HH.1 Corporate Profile
HH.2 Business Segment Analysis
HH.3 Financial Analysis
HH.4 Ratio Analysis
HH.5 Major Products & Services
II. Hanmi Science Co Ltd
II.1 Corporate Profile
II.2 Business Segment Analysis
II.3 Financial Analysis
II.4 Ratio Analysis
II.5 Major Products & Services
JJ. Harbin Pharmaceutical Group Co. Ltd.
JJ.1 Corporate Profile
JJ.2 Business Segment Analysis
JJ.3 Financial Analysis
JJ.4 Ratio Analysis
JJ.5 Major Products & Services
KK. Jubilant Life Sciences Ltd
KK.1 Corporate Profile
KK.2 Business Segment Analysis
KK.3 Financial Analysis
KK.4 Ratio Analysis
KK.5 Major Products & Services
LL. Mylan Laboratories Ltd
LL.1 Corporate Profile
LL.2 Business Segment Analysis
LL.3 Financial Analysis
LL.4 Ratio Analysis
LL.5 Major Products & Services
MM. Pharmstandard OJSC
MM.1 Corporate Profile
MM.2 Business Segment Analysis
MM.3 Financial Analysis
MM.4 Ratio Analysis
MM.5 Major Products & Services
NN. Ranbaxy Laboratories
NN.1 Corporate Profile
NN.2 Business Segment Analysis
NN.3 Financial Analysis
NN.4 Ratio Analysis
NN.5 Major Products & Services
OO. Sun Pharmaceutical Industries
OO.1 Corporate Profile
OO.2 Business Segment Analysis
OO.3 Financial Analysis
OO.4 Ratio Analysis
OO.5 Major Products & Services
PP. Taisho Pharmaceutical Co., Ltd.
PP.1 Corporate Profile
PP.2 Business Segment Analysis
PP.3 Financial Analysis
PP.4 Ratio Analysis
PP.5 Major Products & Services
QQ. Chiesi Farmaceutici SpA
RR. Dong-A Pharmaceutical Co. Ltd
SS. Jiangsu Yangtze River Pharmaceutical Group Co., Ltd.
TT. Yunnan Baiyao Group
Section 4: Glossary of Terms

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook